Microbiome therapeutics technology reimagined.
Expora Therapeutics develops cost-effective oral exosome therapies to address life-threatening inflammatory diseases—starting with necrotizing enterocolitis (NEC), a leading cause of infant mortality.
Microbiome therapeutics technology reimagined.
Expora Therapeutics develops cost-effective oral exosome therapies to address life-threatening inflammatory diseases—starting with necrotizing enterocolitis (NEC), a leading cause of infant mortality.
Our Mission
Medicines from Probiotics
Our BEX™ platform technology unlocks scalable manufacturing and engineering of bacterial extracellular vesicles (exosomes) for affordable, safe, and effective delivery of therapeutics to gastrointestinal tissues—starting in neonatal care and extending to chronic inflammatory diseases and cancer.
Our Mission
Medicines from Probiotics
Our BEX™ platform technology unlocks scalable manufacturing and engineering of bacterial extracellular vesicles (exosomes) for affordable, safe, and effective delivery of therapeutics to gastrointestinal tissues—starting in neonatal care and extending to chronic inflammatory diseases and cancer.
Meet BEX-114
A Safer, Smarter Approach to NEC Prevention
BEX-114 is a sterile, oral exosome therapy that enhances the benefits of probiotic bacteria and mitigates infection concerns in sensitive preterm babies for potential best-in-class NEC prevention.
Oral delivery - no injections
Sterile formulation with no live bacteria
More effective than live probiotics in preclinical NEC models
Transformative therapeutic potential beyond NEC
Meet BEX-114
A Safer, Smarter Approach to NEC Prevention
BEX-114 is a sterile, oral exosome therapy that enhances the benefits of probiotic bacteria and mitigates infection concerns in sensitive preterm babies for potential best-in-class NEC prevention.
Oral delivery - no injections
Sterile formulation with no live bacteria
More effective than live probiotics in preclinical NEC models
Transformative therapeutic potential beyond NEC
Feature
Our Platform Is Built for Scalability, Safety, and Expansion
The BEX™ platform unlocks bacterial exosome manufacturing at scale with Generally Regarded As Safe (GRAS) probiotic producer cells and orders of magnitude lower costs than conventional exosome therapies, creating a foundation for future therapeutics.
3-Fold Potency Increase
60x increased exosome production
CMC Optimization
Proprietary purification and CMC optimization
Application Ready
Cargo loading for future engineered therapies
Patented
Patent-backed platform with trade secret extensions
Feature
Our Platform Is Built for Scalability, Safety, and Expansion
The BEX™ platform unlocks bacterial exosome manufacturing at scale with Generally Regarded As Safe (GRAS) probiotic producer cells and orders of magnitude lower costs than conventional exosome therapies, creating a foundation for future therapeutics.
3-Fold Potency Increase
60x increased exosome production
CMC Optimization
Proprietary purification and CMC optimization
Application Ready
Cargo loading for future engineered therapies
Patented
Patent-backed platform with trade secret extensions
$1.5B Beachhead Market
A Singular Mission
Expora is targeting NEC prevention in a clearly defined, rare pediatric patient population with urgent unmet need — with expansion potential into multi-billion-dollar disease areas.
Each year in the U.S., approximately 60,000 very low birthweight (VLBW) infants are born. Necrotizing enterocolitis (NEC) affects ~8% these infants, translating to an estimated 4,560 cases annually. The mortality rate for NEC ranges from 10% to 50%, with higher rates observed in extremely low birthweight infants undergoing surgical intervention.
The financial burden is substantial, with the average cost per surgical NEC case estimated between $400,000 and $500,000, leading to an annual national expenditure exceeding $2 billion (20% of all newborn care costs).
Despite the severity and cost implications, there are currently no FDA-approved interventions for NEC. Live probiotics have shown clear clinical benefits in NEC prevention, and were once widely used, but are now discouraged due to rare but serious infections.
Expora’s lead candidate, BEX-114, ideally addresses this critical unmet need. The NEC prevention market in the U.S. is estimated at $600 million, with global potential reaching $1.5 billion.
$1.5B Beachhead Market
A Singular Mission
Expora is targeting NEC prevention in a clearly defined, rare pediatric patient population with urgent unmet need — with expansion potential into multi-billion-dollar disease areas.
Each year in the U.S., approximately 60,000 very low birthweight (VLBW) infants are born. Necrotizing enterocolitis (NEC) affects ~8% these infants, translating to an estimated 4,560 cases annually. The mortality rate for NEC ranges from 10% to 50%, with higher rates observed in extremely low birthweight infants undergoing surgical intervention.
The financial burden is substantial, with the average cost per surgical NEC case estimated between $400,000 and $500,000, leading to an annual national expenditure exceeding $2 billion (20% of all newborn care costs).
Despite the severity and cost implications, there are currently no FDA-approved interventions for NEC. Live probiotics have shown clear clinical benefits in NEC prevention, and were once widely used, but are now discouraged due to rare but serious infections.
Expora’s lead candidate, BEX-114, ideally addresses this critical unmet need. The NEC prevention market in the U.S. is estimated at $600 million, with global potential reaching $1.5 billion.
Partner With Us to Advance the Future of Microbiome Medicine
We’re seeking collaborators, funders, and scientific partners who share our commitment to impact.
Partner With Us to Advance the Future of Microbiome Medicine
We’re seeking collaborators, funders, and scientific partners who share our commitment to impact.
Partner With Us to Advance the Future of Microbiome Medicine
We’re seeking collaborators, funders, and scientific partners who share our commitment to impact.